Vendor Intelligence Report: Pure Rawz

Executive summary

Across 29 Finnrick lab tests, Pure Rawz passed 13 and failed 16 — an overall pass rate of 45%. The signal is product-specific, not a blanket verdict. Retatrutide and Tirzepatide are the comparatively stronger choices if a buyer is constrained to this catalog, while CJC-1295 is the clear avoid and BPC-157 is materially weak. Ratings also fall as grading gets stricter.

The storefront’s public identity is more fragmented than its branding. FDA, BBB and USPTO records point to a Tennessee operating footprint and connect the control trail to Prometheuz Health, a TRT-clinic brand. The FDA warning letter did not cite peptides, but it did cite Pure Rawz for human-use marketing of tianeptine products despite research-use positioning.

Product provenance is another pressure point. Pure Rawz markets USA-made compounds, yet its own FAQ describes packages moving from the EU to the US before final delivery. Its named-lab COAs are real artifacts, but the cited purity testing expressly excludes sterility, endotoxins, heavy metals and pH.

Fulfillment risk is separate from vial quality. Payment instructions include irreversible rails and directions to omit product, order or store identifiers from notes; the BBB record includes an F profile and a Semaglutide non-delivery complaint paid by Zelle. The full report also maps medium-confidence sister-brand and coupon/referral evidence without treating community claims as filings.

Inside the full report:

• Appendix A lab data, per-product pass/fail rates and methodology-divergence charts for all 7 tested peptides
• FDA Warning Letter MARCS-CMS 715218 analysis and the unresolved close-out check
• Corporate and address trail from FDA, BBB and USPTO records, including Prometheuz Health trademark filings
• EU-to-US supply-chain claim check and MZ Biolabs COA-scope limitations
• Sister-brand and promotion review covering BehemothLabz, RCD.Bio, RavenLabs, Amino Asylum, referral codes and BBB fulfillment records

Risk assessment

• Multi-product peptide quality inconsistency — high: Finnrick recorded 29 tests with 13 pass / 16 fail; CJC-1295 was 0/4 pass at 18.95%, with BPC-157, Retatrutide, Semaglutide and Tirzepatide each split 2/4.
• Injectable COA scope gap — medium: Vendor COAs from MZ Biolabs cover purity but MZ states standard purity testing does not cover sterility/endotoxins, heavy metals or pH for injectable peptides.
• Origin misrepresentation and supply-chain opacity — high: Pure Rawz markets USA-made compounds while its FAQ says packages travel from the EU to the US before USPS delivery; no named EU supplier was verified.
• Regulatory enforcement risk — high: FDA Warning Letter MARCS-CMS 715218 cited PureRawz/Seann Gloss for unapproved Tianeptine products marketed for human use; no close-out was found.
• Payment-recourse and fulfillment-loss risk — high: Zelle/crypto/Venmo instructions minimize dispute trails; BBB lists an F rating and a $206 Zelle Semaglutide non-delivery scam report.
• Sister-brand and network enforcement risk — medium: Community and affiliate evidence links Pure Rawz to BehemothLabz, RCD.Bio, RavenLabs and Amino Asylum; Amino Asylum was federally raided in 2025.
• Undisclosed affiliate-promotion risk — medium: Affiliate scan found 19 promotion records; 18 carried referral codes or links and none had clear disclosure, including DESN7, ROAR69 and ref=417 placements.
• Brand-channel confusion risk — medium: Multiple Pure Rawz domains/review profiles and SEO coupon/referral pages surfaced; no authoritative official-channels or authorized-reseller list was located.